Open AccessAmprenavir Inhibitory Quotient and Virological Response in Human Immunodeficiency Virus-Infected Patients on an Amprenavir-Containing Salvage Regimen without or with Ritonavir
Author(s) -
Xavier Duval,
C. Lamotte,
Ester Race,
Diane Descamps,
Florence Damond,
François Clavel,
Catherine Leport,
Gilles Peytavin,
JeanLouis Vildé
Publication year - 2002
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.46.2.570-574.2002
Subject(s) - amprenavir , ritonavir , salvage therapy , virology , regimen , protease inhibitor (pharmacology) , medicine , enfuvirtide , reverse transcriptase inhibitor , sida , gastroenterology , virus , pharmacology , biology , viral disease , viral load , protease , immunology , antiretroviral therapy , chemotherapy , hiv 1 protease , enzyme , biochemistry , antigen , gp41 , epitope
The efficacy of an amprenavir (APV)-containing therapy without (group A) or with (group B) ritonavir was assessed in patients with failure of previous protease inhibitor therapy for human immunodeficiency virus (HIV) infection. The mean minimal plasma APV concentrations in groups A and B were 58 and 1,320 ng/ml, respectively, corresponding to APV inhibitory quotients of 0.2 (range, 0.03 to 0.70) and 7.0 (range, 1.4 to 145), respectively. At week 24, 2 of 8 and 13 of 14 patients in groups A and B, respectively, had <200 HIV RNA copies/ml of plasma, including 4 of 5 patients infected with APV-resistant viruses.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom